Edison Oncology Holding

Edison Oncology is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for cancers with significant unmet needs, particularly those involving the central nervous system. The company's primary focus is on its lead candidate, EO1001, a potent, irreversible, and brain-penetrant small molecule inhibitor of the ErbB receptor tyrosine kinase family, including EGFR, HER2, and HER4. Unlike many other kinase inhibitors, EO1001 is specifically designed to cross the blood-brain barrier, making it a promising candidate for treating primary brain tumors and brain metastases from other solid tumors. Edison Oncology is currently advancing EO1001 through Phase 2 clinical trials for indications such as glioblastoma multiforme and HER2-positive brain metastases. The company operates as a subsidiary of Ault Alliance and leverages strategic partnerships to accelerate its clinical development programs.